Navigation Links
KineMatik Group Ltd. Appoints Michael G. Jarjour as President & CEO
Date:1/21/2009

Former Organon VP of Global Marketing Will Oversee Life Sciences Software Group

Cork, Ireland (PRWEB) January 21, 2009 - The KineMatik™ Group LTD ("KineMatik"), providers of software solutions for managing scientific R&D knowledge, information and processes, announced that it has appointed Michael G. Jarjour as President & CEO.

Mr. Jarjour, with more than eighteen years of experience in the pharmaceutical research and healthcare technology industries, will lead KineMatik as the company continues to offer leadership and innovation to its pharmaceutical, biotechnology and government clients.

"We are delighted to welcome Michael to the KineMatik team. His extensive experience in sales, marketing, operations and strategic planning, combined with his background and entrepreneurial skills in the life sciences and technology industries, will help us consolidate our position as leaders in the scientific enterprise content of management space," said Harry Lorton, Chairman of the Board of Directors for KineMatik.

"I am pleased to join KineMatik, which has developed an impressive and innovative technology platform," said Mr. Jarjour. "Serving industries so dependent on the rapid, accurate collection of scientific data, KineMatik offers a unique value proposition by supporting secure portfolio, knowledge and project management while lowering costs, increasing productivity and improving time-to-market. In this era of financial and regulatory scrutiny, and intellectual property protection, KineMatik is poised to make a difference in the research and development process."

Before joining KineMatik, Mr. Jarjour was Vice President of Global Marketing for Organon, responsible for leading the $1.5 billion gynecology and urology franchise.

Previously, Mr. Jarjour held key positions at top tier pharmaceutical organizations including Bristol-Myers Squibb, Pharmacia, Warner Lambert and Wyeth. Prior to his work in the pharmaceutical industry, he was the COO and founder of a healthcare technology enterprise for an award-winning, best-in-industry wireless Internet prescribing platform.

Mr. Jarjour holds a BS in Finance from Florida International University and an MBA from the Rutgers University.

About KineMatik: KineMatik brings business methods to the life sciences R&D process, by increasing productivity, accountability and transparency. The company's flagship product, eNovator, is the only software program that lets pharmaceutical, biotechnology and government organizations collaboratively manage their information, knowledge and business processes in one seamlessly integrated and secure system. eNovator, allows researchers to deliver innovation throughout the R&D product development lifecycle. Established in Cork, Ireland in 1999, KineMatik also has offices in London, Princeton, and San Diego. Additional information is available at www.kinematik.com.

Contact:
Jennifer Buchholz
KineMatik
jbuchholz(at)kinematik(dot)com

# # #

Read the full story at http://www.prweb.com/releases/KineMatik_Group/Michael_G_Jarjour/prweb1889204.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. AIM Health Group Inc. and Med-Emerg International Inc. Announce Completion of Previously Disclosed Merger Transaction
2. The Quantum Group Announces Support of Technology Bill Before Congress
3. KJT Group L.L.C. Continues Solid Growth
4. Atlanta Educator Kim Bearden Honored as Healthy Hero by AMERIGROUP Foundation
5. Rochester Medical Announces Settlement With TYCO Healthcare Group, L.P., Now Operating as Covidien Ltd.
6. EBG Advisors and Oldaker Group Form National Health Advisors
7. The Quantum Group and IBM Announce Hosting Agreement for Advanced Healthcare Solutions
8. SOKO Fitness & Spa Group Announces Second Quarter FY2009 Financial Results
9. SOKO Fitness & Spa Group Announces Changes to Previously Issued Financial Statements
10. U.S. and European Advocacy Groups Launch United, Global Campaign to Prevent Cervical Cancer
11. Med-Emerg International Inc. receives court approval for AIM Health Group arrangement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... When it came time to blow out his candles on ... later, the Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised his ... the hospital’s 30th heart transplant recipient. , “He was playing at home, when we ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... financial consultation services to residents in the Sacramento/Folsom region, is initiating a charity ... facility. , The Another Choice Another Chance treatment center in Sacramento works to ...
(Date:12/7/2016)... , ... December 07, 2016 , ... AlignLife clinics nationwide ... Many children are not fortunate enough to receive bountiful gifts wrapped tightly under a ... can bring to the children of the world. , In exchange for generous donations, ...
(Date:12/7/2016)... OR (PRWEB) , ... December 07, 2016 , ... Sharon ... Water, Global Climate Change and Your Health on Voice of America, declared on her ... to call attention to the fact that when these bullies attack leaders in corporate ...
(Date:12/7/2016)... ... December 07, 2016 , ... Delete® - Tattoo Removal and Laser Salon Offers ... Season. Save Up To 33% Off Botox® and Juvederm® Products Now Through December 31, ... with Delightful Deals on Botox® and Juvederm® just in time for the ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... Research and Markets has announced the addition of the ... to 2021" report to their offering. ... , , The immunohistochemistry (IHC) ... a CAGR of 7.3% during the forecast period of 2016 to 2021. ... rapidly increasing geriatric population across the globe are the primary driving the ...
(Date:12/7/2016)... 7, 2016  Palatin Technologies, Inc. ("Palatin") (NYSE ... a previously disclosed underwritten public offering of units ... as sole book-running manager, Roth Capital Partners acted ... as co-manager for the offering. "This ... net proceeds, allowing us to continue advancing bremelanotide ...
(Date:12/7/2016)... , Dec. 7, 2016 DelveInsight,s, ... report provides in depth insights on the ... the Janus Kinase 3 (JAK3) Inhibitors. The ... various stages of development including Discovery, Pre-clinical, ... and Preregistration. Report covers the product clinical ...
Breaking Medicine Technology: